+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cat Allergy Pipeline Market by Product Type, Stage of Development, Route of Administration, Therapy Type, Distribution Channel - Global Forecast to 2030- Product Image
Cat Allergy Pipeline Market by Product Type, Stage of Development, Route of Administration, Therapy Type, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Cat Allergy Pipeline Market by Product Type, Stage of Development, Route of Administration, Therapy Type, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 183 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6011227
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Cat Allergy Pipeline Market grew from USD 4.52 billion in 2024 to USD 4.79 billion in 2025. It is expected to continue growing at a CAGR of 5.72%, reaching USD 6.31 billion by 2030.

Navigating the Evolving Landscape of Cat Allergy Therapeutics

Cat allergy represents a significant and growing public health concern, exerting pressure on healthcare systems and driving demand for innovative therapeutic solutions. Over recent years, the prevalence of feline dander-induced allergic reactions has risen as more households embrace pet ownership and indoor lifestyles. Traditional approaches, such as antihistamines and symptomatic relief measures, continue to address immediate discomfort but fall short of offering long-term control or immunological tolerance.

In response, biopharmaceutical companies have intensified efforts to develop interventions that target underlying immune pathways. These include a broad spectrum of modalities ranging from advanced monoclonal antibodies to precision-engineered vaccines. By examining the current pipeline, stakeholders can better anticipate competitive dynamics, regulatory hurdles, and potential partnership opportunities. This executive summary distills key findings from a rigorous review of clinical trials, patent landscapes, and emerging scientific breakthroughs, laying the groundwork for strategic decision-making.

Breakthrough Technologies Reshaping Treatment Horizons

In recent years, the cat allergy pipeline has undergone transformative shifts marked by technological breakthroughs and paradigm changes. The advent of humanized and fully human monoclonal antibodies has redefined specificity and safety profiles, moving beyond chimeric designs that once dominated preclinical research. Simultaneously, recombinant proteins tailored toward allergen-specific immunotherapies are emerging with enhanced tolerability, while innovative fusion proteins aim to modulate immune responses more precisely.

Small molecule therapies have also evolved, with next-generation histamine receptor antagonists and novel leukotriene inhibitors demonstrating improved pharmacokinetics and reduced off-target effects. Furthermore, vaccine development is transitioning from conventional allergen extract approaches to DNA- and peptide-based platforms, which promise shorter dosing schedules and more robust immunogenicity. These advancements collectively signal a shift from symptomatic relief toward disease modification, opening new avenues for both prophylactic intervention and long-term management.

Assessing the 2025 Tariff Effects on Pipeline Economics

The introduction of revised United States tariff structures in 2025 is poised to alter supply chain economics and pricing strategies across the cat allergy therapeutics market. Import duties on key biologic components, including antibody conjugates and proprietary adjuvants, have risen, creating upward pressure on manufacturing costs for monoclonal antibodies and fusion proteins. Small molecule active pharmaceutical ingredients, often sourced from Asia, are subject to differential duty rates that vary by compound class, influencing procurement choices and inventory planning.

At the same time, vaccines reliant on specialized DNA synthesis and peptide fragmentation face increased import levies, challenging developers to reassess local production versus offshore synthesis. These cumulative tariff impacts necessitate a reevaluation of cost structures and may drive onshoring initiatives for reagent manufacture or encourage strategic alliances to mitigate duty exposure. Payers and providers must remain vigilant to these shifts, as end-user pricing and reimbursement landscapes will inevitably reflect the revised cost base.

Unpacking the Market Through Multifaceted Segmentation

A nuanced understanding of market segmentation illuminates where innovation is most concentrated and where unmet needs persist. Within product type, the monoclonal antibodies category extends across chimeric constructs, humanized variants, and fully human molecules, each offering distinct immunogenicity risk profiles. Recombinant proteins encompass targeted immunotherapies that leverage allergen-specific epitopes as well as multifunctional fusion proteins designed to deliver precision modulation of immune cells. Small molecule therapies are represented by advanced histamine receptor antagonists with improved selectivity alongside novel leukotriene inhibitors that offer oral convenience.

Vaccines span traditional allergen extract formulations as well as next-generation DNA vaccines that encode specific allergenic peptides, and peptide vaccines that present synthetic epitopes to train immune tolerance. Across stages of development, initiatives range from early-phase exploratory preclinical research through Phase I safety assessments, Phase II efficacy trials, and pivotal Phase III studies, concluding with preparations for regulatory approval. Routes of administration diversify between intravenous infusions, subcutaneous injections, oral dosage forms, and topical preparations aimed at mucosal immunization. Therapeutic approaches bifurcate into prophylactic regimens intended to prevent sensitization and therapeutic interventions designed to alleviate established allergic responses. Finally, distribution channels extend through hospital pharmacies, specialty clinics, retail pharmacies, and the growing footprint of online pharmacies, reflecting evolving patient preferences and healthcare delivery models.

Regional Dynamics Driving Clinical and Commercial Success

Regional dynamics are shaping the pace of clinical advancement and commercial adoption in the cat allergy space. In the Americas, robust funding for allergy research, well-established reimbursement frameworks, and an experienced network of contract research organizations accelerate late-stage trials and market entry. Meanwhile, Europe, the Middle East & Africa present a complex tapestry of regulatory environments and healthcare infrastructures, where adaptive pathways and orphan designation schemes can expedite access but require meticulous alignment with regional standards.

Asia-Pacific emerges as a frontier of expansive patient populations and cost-effective manufacturing capabilities. Governments in this region are increasingly prioritizing biotechnology initiatives, fostering collaboration between academic centers and industry. Local clinical trial registries are rapidly populating with studies on recombinant immunotherapies and novel vaccine platforms. These regional nuances not only influence trial site selection but also shape long-term commercialization strategies, making geography a strategic factor in development roadmaps.

Competitive Landscape of Trailblazers and Innovators

Leading the charge in cat allergy therapeutics, several biopharmaceutical companies are shaping the competitive environment through diversified portfolios and strategic collaborations. Large multinational organizations leverage their global regulatory expertise and manufacturing scale to advance monoclonal antibody candidates through late-stage trials. Mid-sized firms are distinguishing themselves with proprietary recombinant protein platforms and first-in-class fusion technologies that address key immunological targets.

Specialty biotech companies, often spin-outs from academic research, focus on novel vaccine constructs and small molecule inhibitors, occupying niche spaces where large players have limited presence. Cross-industry partnerships between diagnostic providers and therapeutic developers are also emerging, aiming to integrate precision diagnostics with tailored treatment algorithms. These alliances are critical for de-risking early-stage programs and securing co-development funding. Collectively, this mix of global heavyweights, agile innovators, and collaborative ventures underscores a multifaceted competitive landscape poised for rapid evolution.

Strategic Imperatives for Sustainable Growth

To navigate this dynamic environment, industry leaders must adopt proactive strategies that balance innovation with operational agility. Prioritizing platform technologies that can be applied across multiple indications will spread development risk and maximize return on investment. Early engagement with regulatory authorities to establish adaptive trial designs and expedited review pathways can reduce time to market, particularly for first-in-class biologics and vaccine candidates.

Additionally, fostering strategic alliances with regional manufacturing partners will help mitigate tariff impacts and secure reliable supply chains. Investing in digital patient engagement tools and real-world evidence platforms will strengthen payer negotiations and support differentiated pricing strategies. Finally, integrating companion diagnostics early in development can optimize patient selection and improve clinical trial success rates, ensuring that therapeutic benefits are demonstrated clearly and compellingly.

Methodical Approach Blending Data and Expert Insight

This analysis is underpinned by a robust research framework combining primary and secondary methodologies. Comprehensive database reviews of clinical trial registries, patent filings, and regulatory submissions provided quantitative insights into program counts, development timelines, and geographic dispersion. In parallel, in-depth interviews with key opinion leaders, industry executives, and clinical investigators offered qualitative perspectives on scientific challenges, development hurdles, and market priorities.

Data was triangulated through cross-referencing market intelligence from peer-reviewed journals, conference proceedings, and proprietary databases to ensure accuracy and currency. The stage-gate approach to segmentation allowed for precise mapping of pipeline projects across development phases and modality categories. Regional analyses incorporated economic indicators, healthcare expenditure data, and regulatory frameworks to contextualize clinical activities and commercialization prospects.

Synthesizing Insights for Future Direction

The cat allergy therapeutics pipeline stands at an inflection point, driven by sophisticated biologics, refined small molecule agents, and next-generation vaccines. Despite rising cost pressures and regulatory complexities, the potential for disease modification and long-term control of feline allergen sensitization is clearer than ever. Strategic alignment across R&D, manufacturing, and commercialization will be critical to transform compelling science into accessible treatments.

By integrating segmentation intelligence, regional dynamics, and competitive analyses, stakeholders can chart informed pathways that anticipate market shifts and capitalize on emerging opportunities. The collective efforts of biopharmaceutical innovators, healthcare providers, and regulatory bodies will determine how swiftly patients worldwide gain access to the next wave of transformative therapies.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Type
    • Monoclonal Antibodies
      • Chimeric
      • Fully Human
      • Humanized
    • Recombinant Proteins
      • Allergen Specific Immunotherapies
      • Fusion Proteins
    • Small Molecule Therapies
      • Histamine Receptor Antagonists
      • Leukotriene Inhibitors
    • Vaccines
      • Allergen Extract Vaccines
      • Dna Vaccines
      • Peptide Vaccines
  • Stage Of Development
    • Phase I
    • Phase Ii
    • Phase Iii
    • Preclinical
    • Regulatory Approval
  • Route Of Administration
    • Intravenous
    • Oral
    • Subcutaneous
    • Topical
  • Therapy Type
    • Prophylactic
    • Therapeutic
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
    • Specialty Clinics
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • ALK-Abelló A/S
  • Stallergenes Greer SA
  • Circassia Pharmaceuticals PLC
  • Allergy Therapeutics PLC
  • DBV Technologies SA
  • Bencard Allergie GmbH
  • HAL Allergy BV
  • LETI Pharma SL
  • Inmunotek SA
  • Viatris Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Cat Allergy Pipeline Market, by Product Type
8.1. Introduction
8.2. Monoclonal Antibodies
8.2.1. Chimeric
8.2.2. Fully Human
8.2.3. Humanized
8.3. Recombinant Proteins
8.3.1. Allergen Specific Immunotherapies
8.3.2. Fusion Proteins
8.4. Small Molecule Therapies
8.4.1. Histamine Receptor Antagonists
8.4.2. Leukotriene Inhibitors
8.5. Vaccines
8.5.1. Allergen Extract Vaccines
8.5.2. Dna Vaccines
8.5.3. Peptide Vaccines
9. Cat Allergy Pipeline Market, by Stage of Development
9.1. Introduction
9.2. Phase I
9.3. Phase Ii
9.4. Phase Iii
9.5. Preclinical
9.6. Regulatory Approval
10. Cat Allergy Pipeline Market, by Route of Administration
10.1. Introduction
10.2. Intravenous
10.3. Oral
10.4. Subcutaneous
10.5. Topical
11. Cat Allergy Pipeline Market, by Therapy Type
11.1. Introduction
11.2. Prophylactic
11.3. Therapeutic
12. Cat Allergy Pipeline Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacies
12.3. Online Pharmacies
12.4. Retail Pharmacies
12.5. Specialty Clinics
13. Americas Cat Allergy Pipeline Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Cat Allergy Pipeline Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Cat Allergy Pipeline Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. ALK-Abelló a/S
16.3.2. Stallergenes Greer SA
16.3.3. Circassia Pharmaceuticals PLC
16.3.4. Allergy Therapeutics PLC
16.3.5. DBV Technologies SA
16.3.6. Bencard Allergie GmbH
16.3.7. HAL Allergy BV
16.3.8. LETI Pharma SL
16.3.9. Inmunotek SA
16.3.10. Viatris Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. CAT ALLERGY PIPELINE MARKET MULTI-CURRENCY
FIGURE 2. CAT ALLERGY PIPELINE MARKET MULTI-LANGUAGE
FIGURE 3. CAT ALLERGY PIPELINE MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS CAT ALLERGY PIPELINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS CAT ALLERGY PIPELINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES CAT ALLERGY PIPELINE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES CAT ALLERGY PIPELINE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CAT ALLERGY PIPELINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CAT ALLERGY PIPELINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC CAT ALLERGY PIPELINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC CAT ALLERGY PIPELINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. CAT ALLERGY PIPELINE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. CAT ALLERGY PIPELINE MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. CAT ALLERGY PIPELINE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY FULLY HUMAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY ALLERGEN SPECIFIC IMMUNOTHERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY HISTAMINE RECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY LEUKOTRIENE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY ALLERGEN EXTRACT VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY REGULATORY APPROVAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PROPHYLACTIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS CAT ALLERGY PIPELINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS CAT ALLERGY PIPELINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES CAT ALLERGY PIPELINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES CAT ALLERGY PIPELINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 64. CANADA CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 65. CANADA CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 66. CANADA CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 67. CANADA CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2030 (USD MILLION)
TABLE 68. CANADA CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 69. CANADA CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 70. CANADA CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 71. CANADA CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 72. CANADA CAT ALLERGY PIPELINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. MEXICO CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 74. MEXICO CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 75. MEXICO CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 76. MEXICO CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2030 (USD MILLION)
TABLE 77. MEXICO CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 78. MEXICO CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 79. MEXICO CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 80. MEXICO CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 81. MEXICO CAT ALLERGY PIPELINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL CAT ALLERGY PIPELINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA CAT ALLERGY PIPELINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA CAT ALLERGY PIPELINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA CAT ALLERGY PIPELINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 110. UNITED KINGDOM CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 111. UNITED KINGDOM CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 112. UNITED KINGDOM CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 113. UNITED KINGDOM CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2030 (USD MILLION)
TABLE 114. UNITED KINGDOM CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 115. UNITED KINGDOM CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 116. UNITED KINGDOM CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 117. UNITED KINGDOM CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 118. UNITED KINGDOM CAT ALLERGY PIPELINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 119. GERMANY CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 120. GERMANY CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 121. GERMANY CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 122. GERMANY CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2030 (USD MILLION)
TABLE 123. GERMANY CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 124. GERMANY CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 125. GERMANY CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 126. GERMANY CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 127. GERMANY CAT ALLERGY PIPELINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 128. FRANCE CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 129. FRANCE CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 130. FRANCE CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 131. FRANCE CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2030 (USD MILLION)
TABLE 132. FRANCE CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 133. FRANCE CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 134. FRANCE CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. FRANCE CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 136. FRANCE CAT ALLERGY PIPELINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 137. RUSSIA CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 138. RUSSIA CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 139. RUSSIA CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 140. RUSSIA CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2030 (USD MILLION)
TABLE 141. RUSSIA CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 142. RUSSIA CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 143. RUSSIA CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 144. RUSSIA CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 145. RUSSIA CAT ALLERGY PIPELINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 146. ITALY CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 147. ITALY CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 148. ITALY CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 149. ITALY CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2030 (USD MILLION)
TABLE 150. ITALY CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 151. ITALY CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 152. ITALY CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 153. ITALY CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 154. ITALY CAT ALLERGY PIPELINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 155. SPAIN CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 156. SPAIN CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 157. SPAIN CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 158. SPAIN CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2030 (USD MILLION)
TABLE 159. SPAIN CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 160. SPAIN CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 161. SPAIN CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 162. SPAIN CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 163. SPAIN CAT ALLERGY PIPELINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 164. UNITED ARAB EMIRATES CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 165. UNITED ARAB EMIRATES CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 166. UNITED ARAB EMIRATES CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 167. UNITED ARAB EMIRATES CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2030 (USD MILLION)
TABLE 168. UNITED ARAB EMIRATES CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 169. UNITED ARAB EMIRATES CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 170. UNITED ARAB EMIRATES CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 171. UNITED ARAB EMIRATES CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 172. UNITED ARAB EMIRATES CAT ALLERGY PIPELINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 173. SAUDI ARABIA CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 174. SAUDI ARABIA CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 175. SAUDI ARABIA CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 176. SAUDI ARABIA CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2030 (USD MILLION)
TABLE 177. SAUDI ARABIA CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 178. SAUDI ARABIA CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 179. SAUDI ARABIA CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 180. SAUDI ARABIA CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 181. SAUDI ARABIA CAT ALLERGY PIPELINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. SOUTH AFRICA CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 183. SOUTH AFRICA CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 184. SOUTH AFRICA CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 185. SOUTH AFRICA CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2030 (USD MILLION)
TABLE 186. SOUTH AFRICA CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 187. SOUTH AFRICA CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 188. SOUTH AFRICA CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 189. SOUTH AFRICA CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 190. SOUTH AFRICA CAT ALLERGY PIPELINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 191. DENMARK CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 192. DENMARK CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 193. DENMARK CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 194. DENMARK CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2030 (USD MILLION)
TABLE 195. DENMARK CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 196. DENMARK CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 197. DENMARK CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 198. DENMARK CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 199. DENMARK CAT ALLERGY PIPELINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 205. NETHERLANDS CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 206. NETHERLANDS CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 207. NETHERLANDS CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 208. NETHERLANDS CAT ALLERGY PIPELINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 209. QATAR CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 210. QATAR CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 211. QATAR CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 212. QATAR CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2030 (USD MILLION)
TABLE 213. QATAR CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 214. QATAR CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 215. QATAR CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 216. QATAR CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 217. QATAR CAT ALLERGY PIPELINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 218. FINLAND CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 219. FINLAND CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 220. FINLAND CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 221. FINLAND CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2030 (USD MILLION)
TABLE 222. FINLAND CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 223. FINLAND CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 224. FINLAND CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 225. FINLAND CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 226. FINLAND CAT ALLERGY PIPELINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 227. SWEDEN CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 228. SWEDEN CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 229. SWEDEN CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 230. SWEDEN CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2030 (USD MILLION)
TABLE 231. SWEDEN CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 232. SWEDEN CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 233. SWEDEN CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 234. SWEDEN CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 235. SWEDEN CAT ALLERGY PIPELINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 236. NIGERIA CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 237. NIGERIA CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 238. NIGERIA CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 239. NIGERIA CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2030 (USD MILLION)
TABLE 240. NIGERIA CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 241. NIGERIA CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 242. NIGERIA CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 243. NIGERIA CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 244. NIGERIA CAT ALLERGY PIPELINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 245. EGYPT CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 246. EGYPT CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 247. EGYPT CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 248. EGYPT CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2030 (USD MILLION)
TABLE 249. EGYPT CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 250. EGYPT CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 251. EGYPT CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 252. EGYPT CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 253. EGYPT CAT ALLERGY PIPELINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 254. TURKEY CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 255. TURKEY CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 256. TURKEY CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 257. TURKEY CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2030 (USD MILLION)
TABLE 258. TURKEY CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 259. TURKEY CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 260. TURKEY CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 261. TURKEY CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 262. TURKEY CAT ALLERGY PIPELINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 263. ISRAEL CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 264. ISRAEL CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 265. ISRAEL CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 266. ISRAEL CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2030 (USD MILLION)
TABLE 267. ISRAEL CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 268. ISRAEL CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 269. ISRAEL CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 270. ISRAEL CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 271. ISRAEL CAT ALLERGY PIPELINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 272. NORWAY CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 273. NORWAY CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 274. NORWAY CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 275. NORWAY CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2030 (USD MILLION)
TABLE 276. NORWAY CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 277. NORWAY CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 278. NORWAY CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 279. NORWAY CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 280. NORWAY CAT ALLERGY PIPELINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 281. POLAND CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 282. POLAND CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 283. POLAND CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 284. POLAND CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2030 (USD MILLION)
TABLE 285. POLAND CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 286. POLAND CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 287. POLAND CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 288. POLAND CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 289. POLAND CAT ALLERGY PIPELINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 290. SWITZERLAND CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 291. SWITZERLAND CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 292. SWITZERLAND CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 293. SWITZERLAND CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2030 (USD MILLION)
TABLE 294. SWITZERLAND CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 295. SWITZERLAND CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 296. SWITZERLAND CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 297. SWITZERLAND CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 298. SWITZERLAND CAT ALLERGY PIPELINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 299. ASIA-PACIFIC CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 300. ASIA-PACIFIC CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 301. ASIA-PACIFIC CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 302. ASIA-PACIFIC CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2030 (USD MILLION)
TABLE 303. ASIA-PACIFIC CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 304. ASIA-PACIFIC CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 305. ASIA-PACIFIC CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 306. ASIA-PACIFIC CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 307. ASIA-PACIFIC CAT ALLERGY PIPELINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 308. ASIA-PACIFIC CAT ALLERGY PIPELINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 309. CHINA CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 310. CHINA CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 311. CHINA CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 312. CHINA CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2030 (USD MILLION)
TABLE 313. CHINA CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 314. CHINA CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 315. CHINA CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 316. CHINA CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 317. CHINA CAT ALLERGY PIPELINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 318. INDIA CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 319. INDIA CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 320. INDIA CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2030 (USD MILLION)
TABLE 321. INDIA CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2030 (USD MILLION)
TABLE 322. INDIA CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 323. INDIA CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 324. INDIA CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 325. INDIA C

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Cat Allergy Pipeline market report include:
  • ALK-Abelló A/S
  • Stallergenes Greer SA
  • Circassia Pharmaceuticals PLC
  • Allergy Therapeutics PLC
  • DBV Technologies SA
  • Bencard Allergie GmbH
  • HAL Allergy BV
  • LETI Pharma SL
  • Inmunotek SA
  • Viatris Inc.

Table Information

Report AttributeDetails
No. of Pages183
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 4.79 Billion
Forecasted Market Value ( USD ) by 2030 $ 6.31 Billion
Compound Annual Growth Rate5.7%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Rhinitis - Pipeline Insight, 2025 - Product Image

Rhinitis - Pipeline Insight, 2025

  • Drug Pipelines
  • 90 Pages
  • Global
From
Allergy Immunotherapy Market by Treatment Type, Allergen Type, Immunotherapy Delivery Form, Technology Platform, Allergy Type, End User, Distribution Channel - Global Forecast to 2030 - Product Image

Allergy Immunotherapy Market by Treatment Type, Allergen Type, Immunotherapy Delivery Form, Technology Platform, Allergy Type, End User, Distribution Channel - Global Forecast to 2030

  • Report
  • 180 Pages
  • Global
From
Birch Pollen Allergy - Pipeline Insight, 2025 - Product Image

Birch Pollen Allergy - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Cedar Pollen Allergy Drug Market by Drug Type, Route of Administration, Distribution Channel, End User, Patient Age Group - Global Forecast to 2030 - Product Image

Cedar Pollen Allergy Drug Market by Drug Type, Route of Administration, Distribution Channel, End User, Patient Age Group - Global Forecast to 2030

  • Report
  • 180 Pages
  • Global
From
Allergies and Hypersensitivity Disease in Animals - Product Image

Allergies and Hypersensitivity Disease in Animals

  • Book

About the Cat Allergy Drug Market

The Cat Allergy Drug market is a subset of the Allergy Drugs market, which is composed of pharmaceuticals used to treat allergies. Cat Allergy Drugs are specifically designed to treat allergies to cats, which can cause symptoms such as sneezing, coughing, and itchy eyes. These drugs are typically administered orally or through injections, and can be used to reduce the severity of symptoms or to prevent them from occurring. Common ingredients in Cat Allergy Drugs include antihistamines, decongestants, and corticosteroids. Some companies in the Cat Allergy Drug market include Allerpet, Inc., Allergy Therapeutics, and Allergan. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.